SEP 14, 2016 7:31 PM PDT

The "Universal Remote" of All Flu Vaccines

WRITTEN BY: Kara Marker
From the first scientist to ever discover broadly neutralizing antibodies, a new candidate for protection from influenza virus has been found. 
Credit: Louise Scharf/Caltech
Wayne Marasco, MD, PhD, was the first scientist to discover broadly neutralizing antibodies in 2009. These are antibodies that, as their name suggests, are able to target and neutralize a wide variety of viruses, and scientists often study broadly neutralizing antibodies in experiments looking for a way to vaccinate against HIV. 

From the Dana Farber Cancer Institute, Marasco and his team described a protein called 3I14 mAb, a broadly neutralizing antibody found to be capable of adapting to recognize different viruses, in their study recently published in the journal Nature Communications.

Marasco and his team analyzed blood samples from seven blood bank donors, where they eventually identified 3I14 as a new antibody. In the lab, they challenged B cells, immune lymphocytes designed to create antibodies during the adaptive immune response, obtained from the blood samples with different types of influenza to see how they would respond. 

Influenza virus mutates so frequently that the vaccine changes every year, which is why one vaccine won’t protect an individual for life. However, one population of B cells in the study appeared to be responsive to every single influenza strain tested. When the researchers isolated the gene responsible for the high-quality protection, 3I14 mAb was discovered.

They also observed just how 3I14 was uniquely able to bind to multiple types of influenza. 3I14 antibodies bind to a part of the virus that doesn’t change even among mutations, called the “stem.”

Next, they challenged the same B cells with a type of bird flu virus called H5 so they could be certain that the cells had never encountered this particular strain of influenza. 3I14 didn’t bind strongly at first, but a single DNA mutation applied in the lab increased its binding strength by tenfold, an incredible improvement considering the mutation was easily induced and is often found in nature.

After more research, scientists found that 3I14 is capable of recognizing and disabling a diverse group of the 18 different strains of influenza virus that infect people all around the world. Specifically, 3I14 antibodies neutralize two main types of influenza virus: group 1 and group 2. 

The influenza virus mutates both suddenly and slowly over time, a tendency exacerbated by the combination of human virus strains with strains that traditionally infect animals. Every year, scientists predict which strains will be most prevalent and develop vaccines for those strains to protect as many people as possible. With a new vaccine based on the 3I14 broadly neutralizing antibody, scientists could protect people from many more variants of influenza virus.
 


Sources: Dana Farber Cancer Institute, Flu.gov, Caltech 
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
JAN 17, 2021
Immunology
A Single Dose Nanoparticle Vaccine for COVID-19
JAN 17, 2021
A Single Dose Nanoparticle Vaccine for COVID-19
In the race for finding the right vaccine for the COVID-19 pandemic, a new vaccine candidate emerged. Researchers at Sta ...
JAN 20, 2021
Immunology
Gut Bacteria's Poison Arrows Exposed
JAN 20, 2021
Gut Bacteria's Poison Arrows Exposed
Bacteria armed with toxin bombs and excruciating abdominal pains caused by raging inflammation in the gut. While the cau ...
FEB 25, 2021
Immunology
Asthma Inhalers Slash Risk of COVID Hospitalization by 90 Percent
FEB 25, 2021
Asthma Inhalers Slash Risk of COVID Hospitalization by 90 Percent
For mild cases of COVID, doctors recommend the usual regimen for getting through a cold or flu: Staying hydrated and res ...
MAR 04, 2021
Immunology
Climate Change Tightens Its Grip on Hay Fever Sufferers
MAR 04, 2021
Climate Change Tightens Its Grip on Hay Fever Sufferers
There’s bad news for pollen allergy sufferers: New research has shown that climate change is making hay fever seas ...
MAR 09, 2021
Immunology
A 'Plug-and-Play' CRISPR Therapy for Flu and COVID
MAR 09, 2021
A 'Plug-and-Play' CRISPR Therapy for Flu and COVID
Researchers have developed a CRISPR treatment that could potentially treat both viruses that cause COVID-19 and influenz ...
MAY 18, 2021
Immunology
Pizza's (Temporary) Effect on the Immune System
MAY 18, 2021
Pizza's (Temporary) Effect on the Immune System
Too much salt isn’t good for you—we know that it can contribute to elevated blood pressure, cardiovascular a ...
Loading Comments...